Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,850 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Recruiting Not applicable Interventional

EHR Intervention to Increase HBOC Genetic Testing

NCT07876349
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Interventions
ELISABETH Evidence-Informed Program (EIP)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

HSCT for High Risk Inherited Inborn Errors

NCT00383448
View directory record Official record
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions
Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 23, 2026, 12:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessment and Validation of Electronic Gas and Bloating Diary

NCT04684849
View directory record Official record
Conditions
Gas, Bloating, Distension, Constipation, Diarrhea
Interventions
APP Diary, Paper Diary
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

NCT01986933
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
nemolizumab (CIM331), Placebo
Drug · Other
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Anniston, Alabama • San Diego, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

NCT01518478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluzone® Intradermal (Sanofi Pasteur Inc.)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 23, 2026, 12:13 PM EDT
Completed No phase listed Observational

A Clinical Investigation of the Vanguard™ Complete Knee System

NCT00698854
View directory record Official record
Conditions
Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Lower Limb Deformity, Complications, Arthroplasty
Interventions
Vanguard™ Complete Knee System, Vanguard™ Patient-Specific Femur
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
8
States / cities
Cedar Rapids, Iowa • Rockville, Maryland • Cape Girardeau, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 12:13 PM EDT
Not listed Not applicable Interventional

Histological Study of the Effects of a 2910 nm Fiber Laser Technology

NCT06317766
View directory record Official record
Conditions
Skin Laxity
Interventions
2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation, 2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation
Device
Lead sponsor
FA Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 12:13 PM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 12:13 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Canoga Park, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

NCT03520036
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
MT-7117 low dose, MT-7117 high dose, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 12:13 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

NCT05529134
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
PTW-002 10 mg/g gel, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 23, 2026, 12:13 PM EDT
Terminated Not applicable Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

NCT00478244
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 12:13 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Study to Investigate the Efficacy of a Digestive Health Dietary Supplement on Post-meal Bloating in Healthy Participants

NCT07516587
View directory record Official record
Conditions
Digestive Health, Abdominal Discomfort, Gas and Bloating
Interventions
Bloat Gummies, Placebo
Dietary Supplement
Lead sponsor
Arrae
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiofrequency and Pulsed Electromagnetic Field Treatment of Skin Laxity of the Mon Pubis, Labia and Vaginal Introitus

NCT02770287
View directory record Official record
Conditions
Skin Laxity
Interventions
Venus Freeze Diamond Polar
Device
Lead sponsor
Venus Concept
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Not applicable Interventional Results available

Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation

NCT00591864
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 23, 2026, 12:13 PM EDT
Not yet recruiting No phase listed Observational

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

NCT06174493
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

NCT00697710
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
50 mg S-777469, 200 mg S-777469, 800 mg S-777469, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 1 Interventional Results available

A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)

NCT00942084
View directory record Official record
Conditions
Herpes Simplex Virus, Neonatal Sepsis
Interventions
Acyclovir
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 45 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Wichita, Kansas • New Orleans, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 2 Interventional

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

NCT01232985
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
RD047-26
Device
Lead sponsor
Oculus Innovative Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 23, 2026, 12:13 PM EDT
Recruiting No phase listed Observational

Mucopolysaccharidosis VII Disease Monitoring Program

NCT03604835
View directory record Official record
Conditions
Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
7
States / cities
Orange, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 12:13 PM EDT
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 23, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

NCT06058650
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Biopsy of Breast, Medical Device Usage and Evaluation, Scintimammography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 12:13 PM EDT